Please login to the form below

companion diagnostic

This page shows the latest companion diagnostic news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

The approval comes on the back of a phase 2 study – called VISION – which enrolled patients with METex14-positive NSCLC based on a just-approved companion diagnostic developed by genome analysis

Latest news

Roche and Illumina partner on genomics for cancer diagnostics

Roche will collaborate with Illumina to complement its comprehensive pan-cancer blood assay TruSight Oncology 500 (TSO 500) with new companion diagnostic (CDx) claims. ... Building on the momentum of other recently established diagnostic and
Lynparza cleared for first-line ovarian cancer use in China

Around 22% of ovarian cancer patients carry a BRCA mutation (15% germline and 7% somatic), which must be identified via a companion diagnostic death.
GSK gets FDA okay for wider use of PARP drug Zejula

Zejula can be used in women who have been treated with three or more prior chemotherapy regimens and whose tumours are HRD-positive, identified using a just-approved companion diagnostic from ... In patients without BRCA mutations, but with a genomic
Roche undercuts price of Bayer cancer drug after winning FDA approval

Roche is working with Foundation Medicine to prepare a filing for FDA approval of the companion diagnostic, but for now no dedicated test is available. ... Vitrakvi also came to market without a companion diagnostic. Rozlytrek and Vitrakvi are part of a
Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Around 22% of ovarian cancer patients carry a BRCA mutation, which must be identified via a companion diagnostic test.

More from news
Approximately 1 fully matching, plus 61 partially matching documents found.

Latest Intelligence

Encouraging signs in biomarker R&D

The response has been a surge of interest in developing novel companion biomarkers, and biomarkers that allow personalisation of therapy. ... The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic
Drug launches to watch in 2019

At the moment there is no companion diagnostic for NTRK fusions so patients need to be identified through genomic profiling techniques such as immunohistochemistry or genetic sequencing approaches, which tend to
Harnessing complexity

This delicate balance between companion diagnostics' clinical utility and their potential confounding impact on patient treatment is a growing dilemma. ... Answering this question in full requires a scientific journey to better understand what a
Diagnostics are rising up the pharma value chain

Diagnostic drivers. It's not just this idea of changing public attitudes that is creating renewed interest in the diagnostics sector; the sector is also influenced by the wider forces affecting ... GlaxoSmithKline and Boehringer Ingelheim have had
Deal Watch table for June 2014

50. NanoString Technologies/ Celgene. Development. Development of a companion diagnostic assay.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Mastering the precision medicine opportunity

Novartis and Roche are two champions of personalised medicine, shaping the area with the launch of targeted treatments combined with a companion diagnostic to support patient identification. ... approval of their new FoundationOne CDx, the first and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...